Isoray Announces Third Quarter Fiscal 2021 Financial Results

Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year   RICHLAND, WASHINGTON – May 13, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...

Isoray Announces Second Quarter Fiscal 2021 Financial Results

Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year   RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...

Isoray Announces Pricing of $45 Million Public Offering

RICHLAND, Wash., February 4, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 36,000,000 shares of...